Table 6 : Relationship between MTX therapy and clinical efficacy, serum drug levels and anti-drug Ab status in between RA and SpA patients.


INFLIXIMAB

  RA patients SpA patients

  N (%) MTX mg/week
median (range)
DAS28
Mean
±SD
IFX serum concentration
mean±SD ng/ml
N° Anti-IFX
Ab positive patients
N (%) MTX mg/week
median (range)
BASDAI
Mean
±SD
IFX serum concentration
mean±SD ng/ml
Anti-IFX
Ab positive patients

MTX users 14 (78) 10 (7.5-15) 3.8±1.78 12.9±14.1 5 18 (41) 7.5 (5-15) 2.51±1.07 10.2±7.8 1
MTX non users 4 (22) 0 3.66±1.19 6.14±4.86 0 26 (59) 0 3.17±1.37 16.6±21.84 6

ADALIMUMAB

  RA patients SpA patients

  N (%) MTX mg/week
median (range)
DAS28
Mean±SD
ADA serum concentration
mean±SD ng/ml
Anti-ADA
Ab positive patients
N (%) MTX mg/week
median (range)
BASDAI
mean±SD
ADA serum concentration
mean±SD ng/ml
Anti-ADA
Ab positive patients

MTX users 21 (78) 10 (7.5-20) 3.71±2.01 44.9±64.9 2 16 (43) 10 (7.5-15) 2.14±1.20 46.9±26.0 0
MTX non users 6 (22) 0 3.10±0.91 15.3±20.0 1 21 (57) 0 3.24±4.46 41,6±36.2 0

ETANERCEPT

  RA patients SpA patients

  N (%) MTX mg/week
median (range)
DAS28
Mean±SD
ETN serum concentration
mean±SD µg/ml
Anti-ETN
Ab positive patients
N (%) MTX mg/week
median (range)
BASDAI
mean±SD
ETN serum concentration
mean±SD μg/ml
Anti-ETN
Ab positive patients

MTX users 24 (75) 10 (5-20) 2.79±1.05 3.65±0.98 3 11 (32) 10 (5-20) 3.4±1.82 3.43±1.18 1
MTX non users 8 (25) 0 2.56±0.87 4.0±0 1 23 (68) 0 2.78±2.0 3.65±0.84 1

Lombardi et al.Journal of Autoimmunity and Cell Responses  2017 4:1DOI : 10.7243/2054-989X-4-1